Literature DB >> 6549772

Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus.

D E Craven, N R Kollisch, C R Hsieh, M G Connolly, W R McCabe.   

Abstract

The epidemiology and therapy of 29 episodes of bacteremia caused by oxacillin- and aminoglycoside-resistant Staphylococcus aureus (OARSA) were compared with 29 episodes of bacteremia due to oxacillin-sensitive S. aureus (OSSA) that occurred during a 36-month period. Patients with bacteremia due to OSSA were younger (P less than 0.05) and were admitted more frequently with acute traumatic injury (P less than 0.01). The overall survival rate one month after persistent bacteremia was 74% for patients with OARSA bacteremia treated with vancomycin compared with 70% for patients with OSSA bacteremia treated with a beta-lactam antibiotic. The results indicate that vancomycin is an effective antibiotic for the treatment of bacteremia caused by OARSA and suggest that its effectiveness is comparable to that of beta-lactam antibiotic treatment of bacteremia due to OSSA.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6549772     DOI: 10.1093/infdis/147.1.137

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge.

Authors:  J M Boyce
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

2.  Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay.

Authors:  M A Pfaller; D J Krogstad; G G Granich; P R Murray
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

3.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

Review 4.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

5.  Oral rifampin and trimethoprim/sulfamethoxazole therapy in asymptomatic carriers of methicillin-resistant Staphylococcus aureus infections.

Authors:  R T Ellison; F N Judson; L C Peterson; D L Cohn; J M Ehret
Journal:  West J Med       Date:  1984-05

6.  Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus.

Authors:  M Pujol; C Peña; R Pallares; J Ayats; J Ariza; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

7.  Autobac susceptibility testing of methicillin-resistant Staphylococcus aureus isolated in an Australian hospital.

Authors:  R A Putland; M D Guinness
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

8.  In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus.

Authors:  S Alvarez; M Jones; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

9.  Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections.

Authors:  H Portier; A Kazmierczak; F Lucht; J C Tremeaux; P Chavanet; J M Duez
Journal:  Infection       Date:  1985       Impact factor: 3.553

10.  Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus.

Authors:  Y Utsui; S Ohya; T Magaribuchi; M Tajima; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.